CSE: PILL | OTCQB: CTABF | FSE:TBF1 · What’s Happening Now. 1. Received our Cannabis Licence,...

Canntab Therapeutics Inc. © 2020

CORPORATE PRESENTATIONCSE: PILL | OTCQB: CTABF | FSE:TBF1

June 2020

Disclaimer

Forward Looking Statements

This presentation contains "forward-looking information" within the meaning of applicable Canadian securities legislation. Generally, forward-looking

information can be identified by the use of forward-looking terminology such as "plans", "expects", or "does not expect", "is expected", "budget", "scheduled",

"estimates", "forecasts", "intends", "anticipates", or "does not anticipate", or "believes" or variations of such words and phrases or state that certain actions,

events or results "may", "could", "would", "might", or "will be taken", "occur", or "be achieved". Forward-looking information is based on the opinions and

estimates of management at the date the information is made, and is based on a number of assumptions and is subject to known and unknown risks,

uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from

those expressed or implied by such forward-looking information, including risks related to market and financing conditions as well as risks associated with the

industries in which the Company operates, changes in project parameters as plans continue to be refined as well as other risk factors. Although the Company

has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may

be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate,

as actual results and future events could differ materially from those anticipated in such information. Accordingly, readers should not place undue reliance on

forward-looking information. The Company does not undertake to update any forward-looking information contained herein.

2Canntab Therapeutics Inc. © 2020June 2020

What We Do

Canntab Therapeutics is the industry leader in solid oral dose formulations of cannabis

with a product line of cannabinoid (THC & CBD) and terpenoid blends in exacting dosages.

13+ patents pending in Canada and the United States cover our proprietary processes and

solid oral dose formulations for extended release, instant release, flash melt and bi-layered

medications.

Our patent pending hard pill cannabinoid formulations provide doctors, patients and the

general consumer with a medical grade solution with all the features you would expect

3

from any prescription or over the counter medication

related to indications such as sleep, pain, and IBS.

Canntab Therapeutics Inc. © 2020June 2020

What’s Happening Now

1. Received our Cannabis Licence, (Processing-Standard, Federal Sales – Medical)

2. We have submitted 60 days Notice of New Cannabis Product to Health Canada.

3. Full scale hard pill manufacturing has begun in Markham, Ontario.

4. Canadian launch of product line with marketing campaign, Q3 of 2020.

5. Clinical trial with Dr. Garbuz at UBC to investigate potentially opioid sparing CBD/THC

formulations in Q3/Q4 2020, as we work towards acquiring Drug Identification Numbers

(DINs).


Strong IP Portfolio

5

13 Patents Pending in the United States and Canada covering our proprietary processesand hard pill formulations for,

INTELLECTUAL PROPERTY CREATES VALUE FOR SHAREHOLDERSBY PROTECTING MARGINS

• Extended Release

• Sustained Release

• Instant Release

• Modified-Release Multi-Layer

• Flash-Melt / Oral Dissolvable Tablet

• Bi-Layered

In August 2019, the Geneva-based International Preliminary

Report on Patentability (“IPRP”) indicated a positive finding of

patentability for our Instant Release Cannabidiol formulation,

meaning that, in their opinion, Canntab’s formulation is not only

patentable but also novel, non-obvious and useful.


Proprietary Process

6

OUR INNOVATIVE PROCESS CREATES A HARD PILL THAT IS UNIQUEIN AN INDUSTRY FLOODED WITH OIL FILLED GEL CAPSULES.

Our patent pending proprietary processes allows us to create hard pill formulations that starts with

cannabis oil in water emulsions, a unique process in the industry to date.

Oil emulsion >> wet granulation >> dried granulation >> blending >> tablet pressing >> coating


CANNTAB Hard Pills Flower Oils Gel Capsules Edibles

Uniform Dosage

Extended Release

Safe Delivery

Discreet

Shelf Life

HighBioavailability

Meeting Medical StandardsCurrent delivery mechanisms such as smoking or vaping cannabis, consuming edibles, gel caps,oils and tincture (droppers) do not provide the medical community, including Doctors, patients orthe average consumer, with an attractive and professional cannabis solution.


Therapeutic Window

CANNTAB’S HARD PILL SOLUTION KEEPS PATIENTS IN THE THERAPEUTIC WINDOW, MAINTAINING SYMPTOM RELIEF WHILE AVOIDING NEGATIVE SIDE

EFFECTS.

Smoking cannabis can result in a large initial dose of the drug followed by a precipitous drop.

Edibles dosing is unpredictable, making it difficult to maintain therapeutic relief.

Our solution, an extended release (XR) tablets with flash melt technology, quickly brings the patient into the therapeutic window and maintains that dosage.


How We Generate Revenue

MANUFACTURINGPROFIT Q3 2020

GEL- CAPSULEPRODUCT SALES

Q3 2020

LICENSING WHITE LABELLINGQ3 2020

HARD PILLPRODUCT SALES

Q3 2020

CBD FROM HEMPCULTIVATED &

EXTRACTED


Commercialization

10

PROPRIETARYFACILITY

Our state-of-the-art manufacturing facility in Markham is fully built out, with all of the equipment needed to commercially manufacture 500K to 3M tablets per day, while conducting ongoing R&D.

FACILITY MANAGEMENT

We received ourCannabis License, (Processing-Standard, Federal Sales -Medical), at our Markham facility, and we have a dedicated team capable of full scalemanufacturing.

DISTRIBUTION ADVANTAGE

We are partnering with top-tier licensed producers for consumer awareness, and to broaden our distribution. We will also pursue export license to Europe and Australia under Euro GMP standards.

WE ARE SCALED UP AND BRINGING THE FUTURE OF MEDICAL CANNABIS TO MARKET

COMMERCIALIZATIONIN CANADA & US

Manufacturing our hard pill formulations has begun in Markham.We intend to begin manufacturing in Florida in late Q2 with Exactus Inc.


Canntab’s Supply & Extraction Advantage

Leveraging our Industrial Hemp License, we have partnered with Nature’s

Nurturing to cultivate high CBD strains of hemp just outside of Guelph

Ontario. The 2019 harvest was completed in October, and we intend to

extract the CBD from this hemp, using equipment from World Class

Extractions.

On October 8th, 2019 we announced the signing of a binding Letter of

Intent to establish a joint venture with World Class Extractions Inc.

(CSE:PUMP). The extraction equipment has been delivered to our

Markham facility and will be utilized immediately, now that we have

our full licence from Health Canada.


Canadian Licensing Strategy

Canntab has received three non growing licenses from Health Canada; Cannabis (Processing-Standard, Federal Sales - Medical), and Cannabis Research. These licenses are for our Markhamfacility in Ontario, Canada.

“With our Cannabis Licenses from Health Canada, we are now in a position to move into full scalemanufacturing and distribution of our next generation of biopharmaceutical cannabinoidsolutions. We plan to roll-out new brands and products for sale, starting this summer,” explainsJeff Renwick, Chief Executive Officer at Canntab. “Canntab intends to be the first to bring timed-release cannabinoid hard pills to market in Canada,” concludes Mr. Renwick.


Health Canada Approval Timeline

Q4 2020Q4 2020Q3 2020Q2 2020

Oral Dose Delivery Systems

These formulations have

been fully developed and

are ready for manufacturing

and distribution.

High-Dosage CBD

Isolate

FlashMelt

Formulations

Bi-LayeredTablets

Extended Release

(XR) Tablets

Instant Release


Sustained Release Core

Immediate Release Film Coating

Approaching the Opioid CrisisThe opioid crisis claimed 4,588 Canadians in 2018. That’s approximately 1 life lost every 2 hours1. Almost 2 million people filled over 9 million prescriptions for opioids in Ontario, in 2015/20162.

Canntab will conduct a clinical study in Q3 2020 with leading orthopedic surgeon Dr. Donald Garbuz at the University of British Columbia. The study aims to showthe potential for reduction of the use of opiates in post-operative pain care using an advanced bi-layer extended release formulation with high CBD and low THC. Q3

Our goal is to gain a Cannabis Drug License, with clinical support,and then Drug Identification Numbers (DINs) for our products.

OUR OVERALL STRATEGY IS TO PROVIDE HEALTH CANADA AND THE MEDICAL COMMUNITY WITH AN EFFICACIOUS MEDICATION IN AN OPTIMAL DELIVERY SYSTEM

141https://health-infobase.canada.ca/datalab/national-surveillance-opioid-mortality.html2http://opioidprescribing.hqontario.ca/Canntab Therapeutics Inc. © 2020June 2020

https://www.statista.com/statistics/760498/total-us-cbd-sales/

https://health-infobase.canada.ca/datalab/national-surveillance-opioid-mortality.html

http://opioidprescribing.hqontario.ca/

Canntab in theUS Market

Our intention is to continue building

relationships that further our US

distribution channels to a growing

$1B+ CBD market3. Canntab’s unique

product line helps our partners

differentiate themselves as the

industry expands.

In the future, we will expand our

production and distribution to include

THC products, when the regulatory

environment stabilizes.

15

3https://www.statista.com/statistics/760498/total-us-cbd-sales/


https://www.statista.com/statistics/760498/total-us-cbd-sales/

Canntab & Exactus Inc.

16

On Nov. 20th, Canntab signed Supply & Distribution agreements with Exactus inc. for the purchase of

hemp-derived CBD oil and the distribution of Canntab’s products in the United States,

on a non-exclusive basis.

A variety of hemp-derived cannabinoids, such as Cannabidiol (CBD)

and Cannabigerol (CBG), in instant release, extended release and

oral disintegrating tablets will be manufactured in Florida.

On Nov. 26th, Exactus signed an endorsement and co-branding deal with Grammy Nominated celebrity

producer and songwriter duo Cool & Dre. Cool himself has been suffering Crohn’s for the last 20 years and

has been very adamant in expressing his personal experience from the use of cannabinoids.


Canntab & Exactus Inc.

17

Canntab will leverage Exactus’ distribution channels, including an e-commerce and Amazon portal

built by a highly experienced team with a track record of successful algorithm-based sales.

Exactus Distribution Strategy

• Targeting Q3 2020 launch of Exactus and Canntab products.

• Green Goddess Extracts product portfolio to target millennial

segment through e-commerce and brick and mortar distribution.

• Paradise CBD skin-care and sun protection product portfolio to

target outdoor and active lifestyle segments.

• DTC and B2B call centre to directly engage with end users and

retailers.


Tablet Economics

Note: Sensitivity Analysis is meant to be illustrative and is not intended to used as a forecast.18Canntab Therapeutics Inc. © 2020June 2020

Capitalization


MAINTAINING ZERO DEBT AND ONLY 30 DAYS OF TRADE PAYABLES

Looking at the Future for Canntab

• Clinical trial with Dr. Garbuz at UBC to investigate potentially opioid sparing CBD/THC formulations in Q3/Q4 2020, as we work towards acquiring Drug Identification Numbers (DINs).

• Further Clinical trials using our patent pending delivery mechanism and formulation capabilities for Sleep, Pain, Arthritis, Irritable Bowel Syndrome, Tempo Mandubular Joint

• Partnering with anyone that wants to use Canntab’s proprietary oral dose delivery system for their own formulations. Our methodology is the optimal and most cost-effective form for pharmaceutical medicines.

• Remaining Debt Free

Canntab Therapeutics Inc. © 2020 20June 2020

Management Team• Former President/CEO of Orbus Pharma

• Business Development for Indukern Chemie AG

• Extensive experience in drug formulation and business development

Jeff Renwick, CEO• Founder First Republic Capital, Co-Founder Fraser

McKenzie, former EVP/Head of IB at Standard Securities

• 28 years of capital markets experience

• MBA in Finance from McMaster University

Richard Goldstein, CFO

• Over 15 years of experience in pharmaceuticals

• Previously Procurement Manager and Compliance Officer for Orbus Pharma Inc.

• More than 15 year of pharmaceutical plant GMP construction experience.

Tommy Larocque, Procurement• Over 20 years of experience in pharmaceuticals

• Previously was Director of R&D for Orbus Pharma Inc.

• An expert in the formulation of cannabinoids.

Laxaminarayan Joshi., Dir. R&D

• 25+ years experience in the manufacturing of pharmaceutical APIs, finished doses, nutraceuticals & Cosmetics.

• Specializes in optimizing processes to allow for scaling up production within a given timeframe, credited with developing 40 lotions and creams.

Robert Lefler, Operations• 20+ years of experience in biotechnology,

pharma, and supplement industries

• Extensive cross-border transactional experience including IP aspects of corporate transaction.

Gavin Bogle, JD, MBA, Legal


Board of Directors• Partner of Garfinkle, Biderman LLP

• Specialized in complex corporate transactions and corporate securities.

• LL.N. cum laude and a Quebec Civil Law degree, both from the University of Ottawa.

Barry M. Polisuk, Chairman• VP/Treasurer of Rompsen Investment Corp. &

former Audit Committee Chair of Enwave Energy.

• Audit Committee Chair of Mission Ready Services.

• MBA, CPA – CGA & member of The Institute of Corporate Directors.

Vitor Fonseca, Audit Committee Chair

• Former President/CEO of Orbus Pharma

• Business Development for Indukern Chemie AG

• Extensive experience in drug formulation and business development

Jeff Renwick, CEO• Founder First Republic Capital, Co-Founder Fraser

McKenzie, former EVP/Head of IB at Standard Securities

• 28 years of capital markets experience

• MBA in Finance from McMaster University

Richard Goldstein, CFO

22Canntab Therapeutics Inc. © 2020

• Former President and CEO of Drug Trading

• Former President and CEO of Katz Group Canada.

• Canntab intends to appoint Larry Latowsky as a Director and Executive Chairman of the Board.

Larry Latowsky, Special AdvisorSpecial Advisor

June 2020

Advisory Board• Former Chief Resident, Mt. Sinai Hospital,

Toronto.

• Former Family Physician to Saudi Royal Family.

• Founder, Regal Health Services.

Dr. Eric Hatashita, MD, CCFOP, FCFP• VP, The Clinical Research Association of Canada.

• President, Canadian Institute for Medical Advancement.

• 20 years experience in clinical trials, including 7 studies on Cannabinoids,

Sabrina Ramkellawan

• Founding COO of Bedrocan Canada, which was acquired by Tweed, now Canopy

• Responsible for first legal transfer of live cannabis plant material from Holland to Canada.

• A professional engineer with an MBA from Schulich.

Hamish Sutherland• President of BLM Marketing Management.

• Over 20 years of pharmaceutical executive experience with a successful track record in business development.

• An global expert in licensing strategies

Bob Woloschuk

• Board member of a number of publicly traded cannabis companies, including Hiku Brands Company

• Global network of contacts in the cannabis industry.

Lorne Gertner“I believe the ultimate solution to the delivery of

Cannabis will be through a hard pill.”- Lorne Gertner


Contact Us

Jeff Renwick, CEO(416) [email protected]

Richard Goldstein, CFO(647) [email protected]

24

Eric Malinski Director of Marketing (416) 996-3762 - [email protected]


Date post:	05-Jun-2020
Category:	Documents
Upload:	others
View:	2 times
Download:	0 times

CSE: PILL | OTCQB: CTABF | FSE:TBF1 · What’s Happening Now. 1. Received our Cannabis Licence,...

Documents